APA (7th ed.) Citation

Yau, T., Park, J., Finn, R. S., Cheng, A., Mathurin, P., Edeline, J., . . . Sangro, B. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. The lancet oncology, 23(1), 77-90. https://doi.org/10.1016/S1470-2045(21)00604-5

Chicago Style (17th ed.) Citation

Yau, Thomas, et al. "Nivolumab Versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-label, Phase 3 Trial." The Lancet Oncology 23, no. 1 (2022): 77-90. https://doi.org/10.1016/S1470-2045(21)00604-5.

MLA (9th ed.) Citation

Yau, Thomas, et al. "Nivolumab Versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-label, Phase 3 Trial." The Lancet Oncology, vol. 23, no. 1, 2022, pp. 77-90, https://doi.org/10.1016/S1470-2045(21)00604-5.